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Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpes virus
8 (HHV-8) is one of the several carcinogenic viruses that infect humans. KSHV
infection has been implicated in the development of Kaposi’s sarcoma (KS), primary
effusion lymphoma, and multicentric Castleman’s Disease. While KSHV infection is
necessary for the development of KSHV associated malignancies, it is not sufficient
to induce tumorigenesis. Evidently, other co-factors are essential for the progression
of KSHV induced malignancies. One of the most important co-factors, necessary for
the progression of KSHV induced tumors, is immune suppression that frequently arises
during co-infection with HIV and also by other immune suppressants. In this mini-review,
we discuss the roles of co-infection with HIV and other pathogens on KSHV infection
and pathogenesis.
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INTRODUCTION
Kaposi’s sarcoma-associated herpes virus (KSHV), the latest member of the human herpes virus
family has been classiﬁed as a direct carcinogen by the International Agency for Research on Cancer
(Ignatovich et al., 2002) because of its ability to induce sarcomas and lymphomas (IARC Working
Group on the Evaluation of Carcinogenic Risks to Humans, 2012; Chen et al., 2014). Based on
consistent detection of KSHV genome in Kaposi’s sarcoma (KS) and two lymphoproliferative
disorders named Primary eﬀusion lymphoma (PEL) and plasmablastic variant of multicentric
Castleman’s Disease (MCD), KSHV infection has been linked with these malignancies (Chang
et al., 1994; Cesarman et al., 1995; Soulier et al., 1995; Moore and Chang, 2010). Upon infection,
KSHV establishes long-term persistent infection in humans where it manipulates multiple host
signaling pathways, modulates expression of cellular genes, and perturbs cellular homeostasis in
order to thrive in the infected cells (Jarviluoma and Ojala, 2006; Moore and Chang, 2010; Schafer
et al., 2015). Continued cellular homeostasis disturbances associated with KSHV infection can
potentially lead to the development of cancers, however, not all the KSHV infected humans develop
these malignancies, emphasizing the importance of co-factors in determining the development,
and extent of severities of KSHV associated diseases. Since humans serve as natural hosts to
an enormously diverse species of microbes, the complex interplay of co-infecting microbes can
inﬂuence the outcomes of pathologies associated with KSHV infection. The co-infecting microbes
may interact in multifaceted ways such as direct molecular interactions and indirect modulation
of the microenvironment including immune modulation and cytokine deregulation. Co-infection
with other pathogens is likely to be an important determinant of disease progression associated
with KSHV infection but unfortunately, knowledge regarding the impact of co-infecting pathogens
on KSHV associated pathologies are not very clear. Here, we summarize the current information
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regarding the impact of several co-pathogenic infections on
KSHV infection and the associated pathologies.
AN OVERVIEW OF KSHV BIOLOGY
Humans are the natural host of the oncogenic herpesvirus
KSHV. In immune-competent individuals, KSHV establishes
asymptomatic life-long latency following acute infection,
however, it can cause cancers in the infected individuals with
compromised immunity. The virus has a diverse range of in vivo
and in vitro cell tropism but CD19+ B cells appear to be the
primary target for long-term viral latency (Ambroziak et al., 1995;
Lukac and Yuan, 2007; Veettil et al., 2014). Approximately 165
Kb of double stranded DNA genome of KSHV encodes for about
90 open reading frames, 12 precursor micro RNAs (pre-miRNAs)
that are spliced into at least 25 mature miRNAs, and a number
of non-coding and antisense RNAs (Russo et al., 1996; Ganem,
2007; Longnecker and Neipel, 2007; Martin, 2007; Cai et al., 2010;
Arias et al., 2014; Bhutani et al., 2015; Hu et al., 2015). Based on
the expression proﬁles of the viral genes, the life cycle of KSHV
is divided into two distinct phases, latent and lytic (Miller et al.,
1997; Parravicini et al., 2000; Dourmishev et al., 2003; Edelman,
2005; Guito and Lukac, 2015). Latency is a non-productive
phase characterized by the restricted gene expression that aids
the virus in avoiding host immune recognition while allowing
for long-term viral persistence (Guito and Lukac, 2015; Hughes
et al., 2015). Amongst the latently expressed genes, latency
associated nuclear antigen (LANA/LANA-1/ORF73) is the most
abundantly expressed protein consistently detected in all latently
infected tumors. Expression of LANA is absolutely essential for
the maintenance of KSHV latency because of its pleiotropic roles
including replication and maintenance of the viral genome, host
cell survival, proliferation, and immune evasion (reviewed in
Giﬃn and Damania, 2014; Uppal et al., 2014). Lytic phase is
characterized by the expression of a highly ordered cascade of
viral genes that ensures eﬃcient replication of the viral DNA and
its packaging into the new virions. Lytic replication is essential
not only for transmission and dissemination the virus, but also
is considered to be a critical step in the development of KSHV
induced cancers (Lukac and Yuan, 2007; Giﬃn and Damania,
2014; Hughes et al., 2015; Purushothaman et al., 2015). The
switch from latent to lytic infection, is a tightly regulated process
initiated by the expression of KSHVORF50/RTA, the lytic switch
protein considered both necessary, and suﬃcient to drive lytic
replication (Ye et al., 2011; Purushothaman et al., 2015). A large
portion of the KSHV genome is kept silenced during latency
through multiple epigenetic modiﬁcations including histone
deacetylation and repressive histone methylations. However,
during lytic replication, the levels of histone acetylation increases
and repressive histone methylation marks are replaced with
activating histone methylation marks on the viral genome,
allowing for the expression of lytic genes (Pantry andMedveczky,
2009; Toth et al., 2010; Hu et al., 2014; Yu et al., 2014). Some
of the well-known in vivo factors that activate lytic replication
of KSHV include cellular stresses, hypoxia, inﬂammation,
co-pathogenic infections, apoptosis and the immune suppression
state of the infected host (reviewed in Uppal et al., 2014;
Purushothaman et al., 2015). Amongst these, immune status
of the infected host is one of the key factors that controls viral
reactivation; a healthy immune system controls KSHV lytic
reactivation and enforces latency (Lukac and Yuan, 2007).
Appropriate regulation of latent and lytic gene expression is
extremely critical for viral persistence and spread, disturbances
in the regulation of these mechanisms can lead to a development
of cancers. Co-pathogenic infections have a potential to perturb
these regulatory mechanisms in a variety of ways and thus
inﬂuences the outcomes of the pathologies associated with KSHV
infection. Eﬀects of several co-infecting pathogens on KSHV
infection and associated pathologies are summarized here.
KSHV INDUCED PATHOLOGIES
Kaposi’s sarcoma-associated herpesvirus infection is linked to
several malignancies in humans (Kalt et al., 2009). KSHV
infection of endothelial cells lays a foundation for the
development of Kaposi’s Sarcoma (KS), a highly vascularised
tumor of endothelial origin (Ganem, 2006), and the infection of B
cells can cause a rare but aggressive B cell tumor, PEL (Cesarman
et al., 1995). A variant of MCD is another disease associated
with KSHV infection (Chang et al., 1994; Soulier et al., 1995).
More recently, KSHV-inﬂammatory cytokine syndrome (KICS)
has been described as a new inﬂammatory disorder associated
with KSHV infection (Uldrick et al., 2010).
Kaposi’s sarcoma is a slow-growing tumor of endothelial
origin thought to be dependent on viral replication, immune
modulation and production of multiple inﬂammatory cytokines
by the infected endothelial as well as the immune cells
(Knowlton et al., 2014). Interestingly, KS development has
been skewed toward male population. Four histologically
indistinguishable subtypes of KS have been described, (i)
classic KS, a rarely aggressive form predominantly observed
in elderly men of Mediterranean and Middle Eastern ancestry,
(ii) African-endemic KS, associated with signiﬁcant morbidity
and mortality, (iii) iatrogenic KS, frequently found in patients
with pharmacological immune suppression, and (iv) HIV-1 co-
infection associated endemic KS (AIDS-KS), commonly observed
in AIDS patients (reviewed in Schulz and Cesarman, 2015). Of
these, AIDS-KS has the most aggressive clinical manifestations of
all KS subtypes and has become one of the most common cancers
in many Sub-Saharan countries where both, HIV and KSHV are
endemic (Giﬃn and Damania, 2014).
Traditionally KS was considered an AIDS-deﬁning
malignancy because the patients who were at highest risk
of developing KS were HIV-1 co-infected patients with high
HIV-1 viral load and very low peripheral CD4+ T cell counts
(<200 cells/mm3), a count that deﬁnes patient’s progression into
AIDS. Following the introduction of combination antiretroviral
therapies (cART), which are very eﬀective in controlling HIV-1
replication and in restoring CD4+ T cell counts in HIV-1 co-
infected patients, incidences of KS in HIV-1 infected populations
have substantially declined but not quite eradicated (Labo et al.,
2015). Enigmatically, despite of the steep decrease in overall
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incidences of KS in post-cART era, there is a steady increase in
proportions of KS patients diagnosed at CD4+ T cell counts in
excess of 300 cells/mm3, a count generally not associated with
complications arising from opportunistic infections (Maurer
et al., 2007; Krown et al., 2008; Mani et al., 2009; Daly et al.,
2014; Labo et al., 2015). This may be due the fact that highly
eﬀective cART has signiﬁcantly extended the life expectancy
of HIV-1 infected patients; the observed incidences of KS at
higher CD4+ T cell counts may be senescence related entity
resembling the classic KS. Another possibility is that HIV-1
co-infection may have additional inﬂuence on the development
of KS independent of its eﬀects on suppression of CD4+ T cell
immunity; several such potential mechanisms are discussed
later in this review. Regardless of the underlying mechanism,
observed and expected increase in the cases of KS development
at higher CD4+ T cell counts warrants continued research in
the ﬁeld of KSHV in order to reduce the risk of developing such
cancer.
Primary eﬀusion lymphoma is a rare but rapidly progressing B
cell tumor (Simonelli et al., 2003; Ota et al., 2014). PEL typically
presents as malignant eﬀusions without solid tumor mass within
the pericardial, pleural, and peritoneal body cavities of infected
patients but the incidences of extra cavity PEL representation as
mass lesions have also been reported (Deloose et al., 2005; Pan
et al., 2012; Crane et al., 2014). It is an aggressive lymphoma
with a poor prognosis and average time of only 6 months
from the diagnosis. PEL usually arises in the context of HIV
co-infection or other immune suppressed states such as in
recipients of solid organ on immune suppressants (Kim et al.,
2014). EBV co-infection appears to play an active role in the
progression of PEL based on the observation that majority of
PEL patients are also co-infected with EBV (Boulanger et al.,
2005).
Plasmablastic version of MCD is a polyclonal tumor where
lytic replication of KSHV in lymph node plasmablasts promotes
excessive production of pro-inﬂammatory cytokines. KSHV-
MCD is characterized by hypercytokinemia, lymphadenopathy,
splenomegaly, and displays a variety of inﬂammatory symptoms
which can be life threatening in the absence of proper treatment
(Polizzotto et al., 2012; Fajgenbaum et al., 2014). Progression
of KSHV-MCD is much more aggressive in KSHV/HIV co-
infected patients compared to HIV negative patients suggesting
an active role of HIV in accelerating the progression of KSHV-
MCD (Suda et al., 2001; Pinzone et al., 2015). KSHV-MCD is
associated with elevated KSHV viral loads in their peripheral
blood and is accompanied by excessive production of viral
interleukin 6 (vIL6), human interleukin 6 (hIL6), and interleukin
10 (IL10) and their cooperative eﬀect play an important role in
MCD pathogenesis (Oksenhendler et al., 2000; Polizzotto et al.,
2012). Interestingly, these cytokines are potent pro-inﬂammatory
cytokines that can deregulate the control mechanisms of not
only KSHV but also the co-infecting pathogens to aggravate
pathologies associated with the co-infections.
KSHV Induced Cytokine Syndrome (KICS) is a similar
inﬂammatory condition arising as a result of severe systemic lytic
reactivation of KSHV. It is associated with high systemic viral
load and excessive cytokine production, notably, elevated levels
of interleukin 6 (IL-6), and interleukin 10 (IL-10) (Uldrick et al.,
2010; Ballon et al., 2015). These features of KICS are comparable
to the KSHV-MCD without the characteristic lymphadenopathy
(Ballon et al., 2015).
Kaposi’s sarcoma-associated herpesvirus oncogenicity can
be ascribed to its astounding capacity to encode several genes
and miRNAs that target cell survival, apoptosis, and tumor
suppressor pathways (reviewed in Ganem, 2007; Cai et al., 2010;
Schulz and Cesarman, 2015). KSHV’s cell transforming capability
has been demonstrated by its ability to transform several primary
and immortalized cells (Flore et al., 1998; An et al., 2006;
Mutlu et al., 2007; Jones et al., 2012). Despite of demonstrated
oncogenic activity of KSHV in a multitude of experimental
systems, the fact that only a subset of KSHV infected people
develop tumors, strongly suggests that additional factors are
required for causing cancers. Co-pathogenic infections are
emerging as important co-factors in inducing KSHV related
oncogenesis, however, the underlying mechanisms of pathogenic
co-operations on KSHV associated malignancies are still not
well deﬁned. Based on current knowledge, the process of
polymicrobial synergy contributing to the disease progression
can be broadly classiﬁed into three major categories, (i)
deregulation of host immunity associated with the infecting co-
pathogens, (ii) direct interactions between co-infecting microbial
products, and (iii) indirect synergistic mechanisms involving
the modulation of tumor microenvironment through secreted
products. Enormously complex tangles of these mechanisms
contribute to a progression of KSHV induced cancers during
co-pathogenic infections; impact of a few of the well-studied
co-infecting pathogens on KSHV associated oncogenesis is
detailed below.
HIV-1 CO-INFECTION
HIV-1 is one of the most important co-pathogen known to
aggravate KSHV induced pathologies (Bhutani et al., 2015).
Numerous studies have demonstrated that KSHV infected
individuals who are also HIV-1 seropositive, are at substantially
higher risk of developing KS cancers compared to HIV-sero-
negative people (Newton et al., 2003; Bonnet et al., 2004; Grulich
et al., 2007; Rohner et al., 2015). Furthermore, AIDS related KS
is clinically most aggressive form and is also more diﬃcult to
treat compared to the other forms of KS. Incidences of MCD
and PEL tumors are also higher in HIV co-infected patients
compared to KSHV infected HIV-1 negative patients (Engels
et al., 2008; Powles et al., 2009; Krause et al., 2014; Okada et al.,
2014). One of the main eﬀects of uncontrolled HIV infection is
severe deregulation of both adaptive and innate host immunities,
a very important co-factor contributing to the progression of
KSHV pathologies. HIV-1 primarily establishes latency in resting
memory CD4+ T cells and in the cells of monocytic/macrophage
lineage of which CD4+ T cells are highly susceptible to HIV-1
induced cytopathic eﬀects (Abbas et al., 2015). Progressive loss of
CD4+ T cells, thought to stem from chronic immune activation
is a major hallmark of HIV-1 co-infection (Sastry et al., 1996;
Paiardini and Muller-Trutwin, 2013; Kumar et al., 2015; Younas
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et al., 2016). Apparently, CD4+ T cell immunity plays a crucial
role in controlling KSHV lytic replication and consequently is
important for limiting pathogenesis associated with KSHV.
HIV-1 encoded Tat (transcriptional transactivator) is a small
cationic peptide that can penetrate a variety of cells (Rusnati
and Presta, 2002). It has multiple regulatory roles in HIV-
1 replication and host immune deregulation (Fiume et al.,
2015). Several eﬀects of HIV-Tat on KSHV infection have
been noted. HIV-Tat can enhance KSHV infectivity, promote
angiogenesis, and can interact with KSHV proteins to modulate
multiple signaling pathways (Aoki and Tosato, 2007). Tat is
frequently detected in KS spindle cells where it might promote
the growth of spindle cells. Another demonstrated eﬀect of
Tat is inducing apoptosis of CD4+ T cells (Li et al., 1995;
Sastry et al., 1996). Increased risk of developing KS and PEL
associated with low CD4+ T cell count indicates that immune
suppression associated with HIV co-infection plays essential
roles in KSHV induced pathologies (Mbulaiteye et al., 2003;
Rodriguez Salazar et al., 2004; Biggar et al., 2007; Engels
et al., 2008). Interestingly, presentation of MCD seems to be
independent of CD4+ T cell counts, suggesting that additional
factors are necessary for the progression of this disease in HIV-
1 co-infected patients (Mylona et al., 2008). Considering the
importance of weakened host immunity in inducing KSHV
associated pathologies, reconstitution of host immune system
after HAART/cART treatment in HIV infected individuals is
expected to improve clinical outcomes of KSHV pathologies,
but occasionally it can paradoxically worsen manifestation of KS
in a condition called KSHV associated immune reconstitution
inﬂammatory response (IRIS-KS; Shelburne et al., 2002; Letang
et al., 2013). Paradoxical worsening of PEL and MCD with IRIS
has not been yet reported. Suppressed immunity associated with
HIV co-infection also renders the host susceptible to a multitude
of opportunistic infections, many of which can reactivate KSHV
and negatively impact clinical outcomes of KSHV associated
malignancies.
While immune suppression associated with HIV infection
appears to be one of the most important aspects of HIV’s capacity
to induce tumors, reports suggest that it is probably not the only
mechanism that favors KSHV driven oncogenesis (Gallo, 1998).
For example, studies aimed at investigating the distribution of KS
cases in patients with HIV-1 and HIV-2 infections in Gambia,
West Africa, where KSHV infection is endemic, suggested that
KS developed almost exclusively in HIV-1 co-infected patients
despite of similar levels of immune suppression and KSHV sero-
prevalence in both HIV-1 and HIV-2 infected groups (Ariyoshi
et al., 1998; Zeng et al., 2007). In another study, the risk of
developing KS in AIDS patients was found to be several fold
higher compared to the pharmacologically immune suppressed
patients with organ transplant (Mercader et al., 2000).
Chronic inﬂammation associated with HIV-1 infection may
also contribute to HIV-1’s ability to induce tumors in KSHV
infected patients (Fiume et al., 2015). In AIDS-KS, there is
a notable increase in inﬂammatory cytokines such as tumor
necrosis factor a (TNF-a), interferon γ (IFN-γ, interleukins 1 and
6 (IL-1 and IL-6). HIV-1 Tat can penetrate a variety of target
cells to induce the expression of multiple cytokines and growth
factors, some of which can reactivate KSHV lytic replication
cycle (Gallo, 1998; Zeng et al., 2007; Debaisieux et al., 2012).
Release of these inﬂammatory cytokines and soluble factors
foster a microenvironment that is conducive for KS tumors
by promoting angiogenesis and cellular proliferation, or by
deregulating apoptosis (Gallo, 1998; Douglas et al., 2010). For
example, IL-6 and IL-10 induced by Tat in lymphoid cells may
serve as autocrine growth factors for MCD and PEL, respectively
(Aoki and Tosato, 2007; Pinzone et al., 2015). Angiogenesis
is an essential component of KS tumorigenesis. HIV-1 Tat is
postulated to play important roles in initiation and progression
of KS in AIDS patients by promoting angiogenesis through
induction of various cytokines. HIV-1 Tat itself serves as a potent
angiogenic factor that can co-operate with vascular endothelial
growth factor (VEGF) for the activation of KS precursor spindle
and endothelial cells (Albini et al., 1996). Tat also synergizes with
KSHV vIL6 to promote angiogenesis and tumorigenesis through
the regulation of PI3K/PTEN/GSK-3β signaling pathway (Zhou
et al., 2013). Moreover, Tat potentiates tumorigenesis through
its cooperation with KSHV oncoproteins, vGPCR and Kaposin
A (Guo et al., 2004; Chen et al., 2009). Tat has been shown to
promote growth of endothelial cells derived from KS lesions of
AIDS-KS patients (Ensoli et al., 1990). Very recently, a complex
synergy between HIV-1 Tat and KSHV lytic oncogene K1 has
been shown to promote angiogenesis through a mechanism
involving an activation of NF-κB signaling pathway through the
inhibition of IκBα resulting from synergistic induction of cellular
miR8911-5p by Tat and K1 (Yao et al., 2015). HIV-1 Nef is
another secreted protein that can be taken-up by a variety of
cell types. Nef has been shown to cooperate with KSHV vIL6 in
order to induce cell proliferation and tumorigenesis by inducing
AKT signaling (Xue et al., 2014). As mentioned earlier, lytic
reactivation of KSHV from latency is thought to be a critical
step in promoting KSHV associated pathologies. HIV-1 infection
can reactivate latent KSHV genomes either directly, or through
enhanced production of multiple cytokines (Greene et al., 2007).
In a co-culture study of HIV-1 infected T cells (CEM) and latently
KSHV infected B cells (BCBL-1), several cytokines including
oncostatin M (OSM), hepatocyte growth factor/scatter factor
(HGF/SF), and IFN-γ were found to be induced in response to
HIV-1 infection in CEM or BCBL-1 cells. Furthermore, these
cytokines were able to trigger KSHV lytic replication from latent
KSHV genomes (Mercader et al., 2000). HIV-1 infection has
also been shown to directly reactivate KSHV in experimental
settings. Multiple studies have demonstrated that latently KSHV
infected PEL cell line, BC-3 can be infected by HIV-1 and these
dually infected cells can support productive replication of HIV-1.
HIV-1 co-infection of BC-3 can directly reactivate latent KSHV
genomes through potent induction of KSHV lytic master switch
protein, RTA (Varthakavi et al., 1999, 2002; Merat et al., 2002).
The eﬀects of Tat on reactivation of latent KSHV genomes
are partially attributable to Tat’s ability to induce inﬂammatory
cytokines and synergize with KSHV proteins. In addition to
directly or indirectly activating KSHV lytic replication, HIV-
1 infection can also enhance infectivity of KSHV virions in
endothelial and other cells through the expression of Tat, most
likely by concentrating KSHV virions on the surface of the cell
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(Aoki and Tosato, 2004). Reciprocally, KSHV infection can also
induce robust replication of HIV-1 in vivo and in vitro (Caselli
et al., 2001, 2003, 2005; Mercader et al., 2001). Interestingly,
KSHV is capable of infecting human tonsillar CD4+ T cells
ex-vivo, the primary targets of HIV-1 infection, although KSHV
infection in these cells seems to be abortive (Myoung and Ganem,
2011). This ﬁnding is important because it highlights KSHV’s
potential to inﬂuence HIV-1 biology in HIV-1’s primary target
CD4+ T cells (Karijolich et al., 2014). Several KSHV proteins
including KSHV RTA/ORF50, LANA/ORF73, and KIE-2/ORF45
have been shown to modulate the activity of the long terminal
repeat region (LTR) of HIV-1 through their cooperative actions
with HIV-1 Tat (Huang et al., 2001; Hyun et al., 2001; Caselli
et al., 2003; Karijolich et al., 2014). In addition to boosting-up
HIV-1 replication, these interactions enhance the susceptibility
of cells to HIV-1 infection. For example, KSHV ORF50/RTA
stimulates HIV replication in HIV permissive T and B cells, but it
also induces transient permissiveness of HIV-1 infection in HIV-
1 non-susceptible glial cells (Caselli et al., 2003). When HIV-1
and KSHV genomes co-exist in the same cellular environment,
both the viruses increase each other’s gene expression through
active bidirectional talks (Huang et al., 2001). KSHV ORF45 has
been identiﬁed as a part of ampliﬁcation loop for activating HIV-
1 LTR in cooperation with HIV-1 Tat and Vpr. KSHV-ORF45
stimulates the expression of Tat andVpr and these proteins return
the favor by inducing the expression of KSHV protein ORF45.
KSHV infection thus may serve as an important co-factor for
HIV-1 progression. While tumor cells naturally co-infected with
HIV-1 and KSHV have not been identiﬁed yet, these ﬁndings
support a possibility of existence of HIV-1 and KSHV dually
infected reservoirs in natural settings. Both the viruses can infect
cells of monocytic/macrophage, B-cell, and T-cell lineages (Merat
et al., 2002; Myoung and Ganem, 2011). Interestingly, a direct
molecular interaction between HIV-1 and KSHV components
has also been observed in experimental systems. The carboxy
terminal domain of LANA physically associates with Tat protein
in vitro to induce a robust transactivation of LTR by targeting
the core enhancer element of LTR (Hyun et al., 2001; Karijolich
et al., 2014). Existence of direct molecular interaction between
these two viruses suggests that they may have evolved to
interact with each other in nature and co-existence of both
the viruses in the same cellular compartments that are yet to
be identiﬁed is likely. Collectively, all these ﬁndings provide a
substantial evidence for existence of indirect as well as direct
molecular interactions between KSHV and HIV-1 that can
stimulate carcinogenesis in the host co-infected with both viruses.
Amongst these interactions, HIV-1 Tat seems to exert multiple
immunomodulatory, angiogenic, cell-signal network perturbing
eﬀects, which makes it an attractive therapeutic target for HIV-
1 and KSHV co-infected individuals. Active bidirectional talk
between these two viruses can partially explain exorbitantly high
incidences of KS in HIV-1 infected population and increased
opportunistic infections observed in the patients dually infected
with both of these viruses. Detailed understanding of the
mechanisms of interactions between HIV-1 and KSHV may help
in identifying undesirable synergistic interactions between the
two viruses that can be pharmacologically uncoupled to limit
the damage associated with infections of both of these viruses.
This is particularly relevant in the resource-limited settings of
Sub-Saharan countries where KSHV and HIV-1 infections are
endemic and KSHV associated cancers still remain a public health
burden because of limited access to cART (Orem et al., 2004;
Rohner et al., 2014).
EPSTEIN-BARR VIRUS (EBV, HHV-4)
CO-INFECTION
Epstein-barr virus belongs to the same human γ-herpesvirus
family as KSHV. Like KSHV, EBV is also an oncogenic
lymphotropic virus associated with infectious mononucleosis and
several cancers including an epithelial tumor nasopharyngeal
carcinoma, a B-cell neoplasm, Burkitt’s lymphoma, and gastric
carcinoma (Kempkes and Robertson, 2015). Similar to KSHV
associated malignancies, risk of cancers associated with EBV
infection is higher in immune compromised hosts, including
HIV co-infected individuals. In vivo cell tropism for EBV and
KSHV overlap for B-cells but diﬀer for epithelial (EBV) and
endothelial cells (KSHV). Direct molecular interactions between
KSHV and EBV can occur during chronic viral infections
of B-lymphocytes, a natural latency target for both of these
oncogenic viruses. While KSHV infection is a pre-requisite for
PEL development and EBV infection is not, it is interesting to
note that nearly 70% of PEL cell lines are co-infected with EBV.
Both of these viruses may make the cellular microenvironment
more hospitable for each other and direct or indirect interactions
between them may inﬂuence pathogenesis of PELs (Drexler
et al., 1998; Trivedi et al., 2004; Spadavecchia et al., 2010).
Indeed, a couple of studies have demonstrated that EBV co-
infected PEL cell lines are more tumorigenic compared to the
EBV negative PEL cell lines (Boshoﬀ et al., 1998; Trivedi et al.,
2004).
Several studies have investigated molecular interactions
between two viruses and the results have provided fascinating
insights into the direct molecular interactions between two
viruses. Apparently, these two viruses can suppress lytic
replication of each other in dually infected cells (Krithivas
et al., 2000; Xu et al., 2007; Jiang et al., 2008; Spadavecchia
et al., 2010). Like KSHV, EBV also primarily establishes latency
upon infection in B lymphocytes and periodically reactivates
to lytic replication cycle for production and dissemination
of the virus (Murata, 2014). An immediate-early protein
of EBV, Zta (EBV-Z/BZLF1/ZEBRA/EB1) initiates the lytic
replication cascade of EBV (Wang et al., 2009). In KSHV
and EBV dually infected cells, this EBV protein physically
interacts with KSHV lytic cycle initiator protein, RTA/ORF50
(K-RTA). The interaction occurs through leucine heptapeptide
repeat (LR) region of K-RTA and leucine zipper region of
EBV-Z resulting into an inhibition of both the molecules
and consequent inhibition of respective lytic replication cycles.
KSHV-RTA or EBV-ZTA, whichever is predominantly expressed,
can eﬀectively suppress the other virus’s lytic replication and
in the case of PEL cell lines, KSHV appears to be the
dominant genome (Jiang et al., 2008; Ueda et al., 2011). Another
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distinct mechanism leading to a suppression of KSHV lytic
replication by EBV involves an EBV latent membrane protein
1 (LMP1), which is a major EBV oncoprotein essential for the
establishment of EBV latency and for the oncogenic processes
driving B-cell transformations (Jiang et al., 2008; Kempkes
and Robertson, 2015). KSHV-RTA induces the expression
of EBV-LMP1 in latently EBV infected cells and LMP-1 in
turn suppresses KSHV lytic replication by downregulating
KSHV-RTA expression. While EBV-ZTA suppresses the lytic
reactivation of only KSHV, expression of EBV-LMP1 suppresses
the lytic replication of both, EBV and KSHV. Furthermore,
KSHV can reinforce EBV latency by transactivating the EBV
latency promoters through K-RTA through RBP-Jk, the cellular
DNA-binding component of the Notch signal transduction
pathway (Spadavecchia et al., 2010). An indirect mechanism
of latent/lytic modulation of these two viruses during co-
infections has also been noted. A recent study showed that
activation of signal transducer and activator of transcription
3 (STAT-3), a potent cellular transcription factor that is
up-regulated independently during both KSHV and EBV
infections, can suppress lytic replication of KSHV through
the suppression of KSHV-RTA promoter (Lui et al., 2009;
King et al., 2015). This seems to be dependent on the
activation of the cellular transcriptional co-repressor Krüppel-
associated box domain-associated protein 1 (KAP1/TRIM28;
King et al., 2015). Since several of the latent viral proteins
of both these viruses are tumorigenic and because long-term
latency oﬀers prolonged periods of synergistic actions of these
proteins including modulation of cell signaling and induction
of inﬂammatory cytokines; co-infection with both the viruses
may enhance the tumorigenic potential of the co-infected
cells.
Both of these oncogenic viruses may have evolved various
mechanisms for mutual suppression of lytic reactivation in order
to compete for limited resources available during unfavorable
cellular conditions, however, long-term latency resulting from
the co-infection of both of these viruses may also oﬀer mutual
survival advantages by helping them hide from the radar of the
host’s immune surveillance. For example, several of the EBV
encoded microRNAs (miRNAs) target crucial cellular pathways
including apoptosis, cell-cycle control and immune-modulation
pathways whose deregulation is important for long-term viral
persistence of both KSHV and EBV (Gottwein et al., 2011;
Riley et al., 2012; Haecker and Renne, 2014). Interestingly,
there is a signiﬁcant functional overlap between the miRNAs
of KSHV and EBV in repressing the same cellular pathways
despite of structural disparities between the miRNAs of these
viruses. This functional synergy underscores the importance of
co-infections in modulating host microenvironment to favor the
viral persistence.
In addition to promoting EBV latency, KSHV infection
can also enhance the infectivity of EBV indicating that EBV
co-infection may confer survival advantages to KSHV. In
KSHV infected B-lymphocytes, K-RTA has been shown to
increase the infectivity of EBV through the upregulation of
CD21 expression, a receptor for EBV entry (Chang et al.,
2005).
HUMAN CYTOMEGALOVIRUS (HCMV,
HHV-5) CO-INFECTION
Human cytomegalovirus is an archetypical member of
β-herpesvirus subfamily. HCMV infection is highly prevalent
worldwide but has variable seropositivity rates, and is endemic
in developing countries, especially in sub-Saharan Africa where
KSHV infection is also endemic (Adland et al., 2015). Following
primary infection, HCMV can establish latent infection in
hematopoietic progenitor cells (HPCs) or in monocytes
(Tarrant-Elorza et al., 2014). Primary infection with HCMV is
largely asymptomatic in healthy individuals, but its reactivation
could cause signiﬁcant morbidity and mortality in immune
compromised patients; notably, these patients are also at higher
risk for developing KSHV associated malignancies. HCMV
has a very diverse cell tropism including hematopoietic cells,
parenchymal cells, epithelial cells, endothelial cells, ﬁbroblasts
and smooth muscle cells (Sinzger et al., 2008). Of these, epithelial
cells, endothelial cells, ﬁbroblasts and smooth muscle cells
are the predominant targets for bursts of lytic replication
(Sinzger et al., 2008; Tarrant-Elorza et al., 2014). Notably,
monocytes support long-term latency for both of these viruses.
Since HCMV cell tropism coincides signiﬁcantly with KSHV
cell tropism, in vivo interactions between these two viruses,
although not discovered yet, are likely to exist. Presence of
HCMV has been detected in KS lesions and experimental
evidences suggest that HCMV co-infection can induce KSHV
lytic replication. Co-infection of HCMV in experimental
systems is known to activate KSHV lytic replication cycle in
a variety of cells including endothelial cells, ﬁbroblasts, and
keratinocytes (Vieira et al., 2001; Lu et al., 2005; Wells et al.,
2009). The mechanism of KSHV reactivation by HCMV involves
an activation of KSHV-RTA by UL112-113 region of HCMV
that encodes four nuclear phosphoproteins via alternative
splicing with essential roles in HCMV DNA replication (Park
et al., 2006). Although it is unclear whether these HCMV
proteins interacts with the RTA promoter directly (Wells et al.,
2009). HCMV infection thus may inﬂuence KSHV associated
pathogenesis in the host co-infected with both the viruses.
Mutual interactions between KSHV and HCMV, although
not well studied, hold a high signiﬁcance in the context of
immune suppression, which is a strong co-factor for the
reactivation of both the viruses and the progression of associated
pathologies. These interactions are especially more relevant
in sub-Saharan Africa where HIV, KSHV, and HCMV all are
endemic.
HHV-6 CO-INFECTION
Human herpesvirus-6 is another non-oncogenic herpesvirus
belonging to the β-herpesvirus subfamily. The virus is classiﬁed
into two variants, HHV-6A and HHV-6B (Ablashi et al., 2014).
Primary infection of HHV-6B is associated with exanthem
subitum (also known as roseola infantum) and other febrile
illnesses, while pathogenesis of HHV-6A is not well deﬁned
(Yamanishi et al., 1988; Mori et al., 2015). HHV-6 infection is
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widespread. Primary infection of the virus is thought to occur
before the age of 3 years in most children, and nearly 95% of
adult population is estimated to be infected with this virus (Zerr
et al., 2005). Following primary infection, HHV-6 establishes a
life-long latency, which can reactivate to lytic replication during
the phases of immune suppression. Viral reactivation often
has severe manifestations in immune-compromised patients;
HHV-6 lytic reactivation has been implicated in hepatitis,
pneumonitis, reactivation of cytomegalovirus (CMV), fever and
rash, myelosuppression, and encephalitis (Zerr et al., 2005). The
virus has a broad in vivo and in vitro cell tropism; active HHV-6
infection has been detected in a variety of cells including CD4+
T cells, monocyte/macrophage cells, dendritic cells, epithelial
cells, and astrocytes (Campadelli-Fiume et al., 1999). This means
that HHV-6 has a potential of co-infecting KSHV infected
cells, especially the cells of monocyte/macrophage lineage and
inﬂuence KSHV gene expression thorough direct interactions.
Indeed, HHV-6 infection has been detected in the monocytes
inﬁltrating KS lesions (Bovenzi et al., 1993; Kempf et al., 1997).
It is noteworthy that monocytes support productive KSHV
infection and are considered an important reservoir for the
maintenance of high KSHV load in KS tumors (Blasig et al.,
1997). Furthermore, in an experimental setting where latently
KSHV infected cells, BCBL-1 were fused with latently HHV-6
infected JJahan T cells, a reactivation of KSHV from latency
was observed, indicating a direct interactions between molecular
components of both the viruses (Lu et al., 2005). Although the
existence of HHV-6 and KSHV dually infected cells in vivo is
rare, detection of HHV-6 in a wide range of tissues suggests
that HHV-6 can inﬂuence KSHV replication thorough soluble
factors in a close vicinity of KSHV infected cells (Campadelli-
Fiume et al., 1999; Asou et al., 2000). HHV-6 infection may
perturb KSHV life cycle by deregulating the expression of a
variety of cytokines including interleukin 1β (IL-1β), tumor
necrosis factor alpha (TNF-α), and interferons (IFNs) (Flamand
et al., 1991; Meeuwsen et al., 2005). Indeed, HHV-6 infection
has been experimentally demonstrated to reactivate KSHV lytic
replication during co-culture of latently KSHV infected PEL cells
with HHV-6 infected T-cells, at least in part through induction
of IFN-γ (Lu et al., 2005). Since HHV-6 infection is ubiquitous,
reactivation of HHV-6 in the context of immune-suppression
may contribute to a progression of KSHV associated pathologies
by further augmenting KSHV lytic replication (Lu et al., 2005).
A recently published case of systemic co-infection of KSHV and
HHV-6 concomitant with very high KSHV viremia in KICS
patient support a possible role of HHV-6 in inducing KSHV
lytic replication, however, further studies are need to establish
HHV-6 infection as a risk-factor for KSHV associated pathologies
(Tamburro et al., 2012). Reciprocal role of KSHV in reactivating
HHV-6 has not been evaluated yet.
CO-INFECTION WITH PERIODONTAL
PATHOGENS
Periodontal diseases are considered the most common chronic
infections in adults (Loesche and Grossman, 2001). They
are characterized by chronic inﬂammation resulting from
complex interactions between host-immunity and polymicrobial
infections of pathogenic bacteria, viruses, fungi and parasites
(Yu et al., 2014). Several herpesviruses including KSHV
have been implicated in the occurrence and progression of
diﬀerent forms of periodontal diseases (Ferreira et al., 2011).
Immune modulation associated with KSHV infection is likely
to favor periodontal pathogenic infection by suppressing host
antimicrobial activity, however, speciﬁc role of KSHV in the
pathogenesis of periodontal disease remains obscure. Conversely,
periodontal pathogens have also been implicated in initiation
and progression of KS in the oral cavity, a common site for KS
lesions (Shiboski and Winkler, 1993). It is estimated that nearly
20% of KS patients ﬁrst develop KS lesions in the oral cavity,
and up to 70% of KS patients eventually develop concurrent
oral and cutaneous KS tumors (Pantanowitz et al., 2013; Yu
et al., 2014). Oral cavity KS lesions may be seen in all variants
of KS but they are more common with AIDS-KS (Fatahzadeh
and Schwartz, 2013). A couple of studies have indicated that co-
infection of periodontal pathogenic microbiota has a potential
to enhance KSHV infectivity and promote lytic replication of
the virus (Shiboski and Winkler, 1993; Morris et al., 2007;
Dai et al., 2012, 2014; Yu et al., 2014). Secreted metabolic
end-products of Porphyromonas gingivalis and Fusobacterium
nucleatum, two of the most common gram-negative oral
periodontal pathogens, may induce KSHV lytic replication by
increasing the acetylation of histones H3 and/or H4 mediated
through the activation of p38 mitogen-activated protein kinase
(MAPK) signaling (Morris et al., 2007). Amongst numerous
metabolic products released into the oral microenvironment
by these two periodontal pathogens, short-chain fatty acids
(SCFAs) are the major ones. At least ﬁve diﬀerent SCFAs are
present in the saliva of the patients with severe periodontitis,
and a majority of these SCFAs act synergistically to promote
KSHV lytic replication by increasing histone acetylation, and
by decreasing repressive histone trimethylation at the promoter
region of the KSHV lytic cascade initiator ORF50/RTA (Yu
et al., 2014). Interestingly, SCFAs simultaneously target multiple
components of host epigenetic repertoire, which can signiﬁcantly
boost transactivation of KSHV latent genome. SCFAs are well
known inhibitors of histone deacetylase class 1 and 2 (HDAC-
1 and 2). Additionally, they also down-regulate a class-3 HDAC
SIRT1 (silent information regulator-1), and two histone-lysine-
N-methyl transferases-EZH2 (enhancer of zeste homolog2) and
SUV39H1 (suppressor of variegation 3-9 homolog1; Yu et al.,
2014). Furthermore, periodontal infection may enhance KSHV
infectivity and modulate viral gene expression. Certain pathogen
associated molecular patterns (PAMPs) including Lipoteichoic
acid (LTA) of a Gram-positive bacteria Staphylococcus aureus,
and Lipopolysaccharide (LPS) of a Gram-negative bacterium,
P. gingivalis have been shown to enhance the infectivity of
KSHV in nearby oral cells and also inﬂuence the expression
of viral genes. These PAMPs of oral pathogens may upregulate
cellular receptors for KSHV entry, increase production of reactive
oxygen species (ROS), and modify intracellular signaling such
as MAPK and NF-κB pathway, and consequently aﬀect KSHV
entry and/or gene expression (Dai et al., 2014). Collectively,
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FIGURE 1 | Potential mechanisms of interactions between Kaposi’s sarcoma-associated herpesvirus (KSHV) and co-infecting pathogens that can
accelerate pathogenesis of KSHV associated malignancies. Many of the commonly observed co-pathogenic infections can perturb KSHV life cycle either
through direct physical interactions with KSHV components or in more complex ways that includes suppression of host immunity and manipulation of cellular
pathways that can make cellular microenvironment more favorable for KSHV replication and/or spread.
these studies support the notion that development of periodontal
disease can be a risk factor for oral Kaposi’s sarcoma. Since
periodontal pathogens can make oral microenvironment more
conducive for KSHV infection and lytic replication, treatment
of oral periodontal disease along with the treatment for Kaposi’s
sarcoma may have more favorable outcomes.
CO-INFECTION WITH PLASMODIUM
FALCIPARUM AND OTHER PARASITES
Malaria is a deadly disease caused by an infection of protozoan
parasite Plasmodium that is transmitted by the bite of infected
female, Anopheles mosquitoes. Currently, ﬁve species of
Plasmodium are known to infect humans of which, P. falciparum
causes the most severe form of the disease and is accountable
for nearly 85% of all malaria cases worldwide. Malaria remains a
public health concern accounting for a yearly global death toll of
nearly 700,000 people (Schmidt et al., 2015). Interestingly, KSHV
infection is highly prevalent in sub-Saharan African countries
where malaria is endemic. Based on the high rates of KSHV
infection in the regions where malaria is endemic, Plasmodium
parasitemia has been proposed as a risk factor for KSHV
infection and several epidemiological studies have demonstrated
that malarial parasite infection is indeed associated with KSHV
seropositivity (Wakeham et al., 2011, 2013; Nascimento, 2014;
Nalwoga et al., 2015). This speculation is further supported by
the fact that the seroprevalence of KSHV and the density of the
malarial vector Anopheles mosquitoes in Italy are proportionate
(Crispo et al., 2001; Coluzzi et al., 2003; Serraino et al., 2003).
Various hypotheses have been proposed to explain how infection
with one of these two pathogens could inﬂuence the infection by
the other pathogen. For instance, malarial parasites are known
to induce severe anemia during their blood stages of infection
(Haldar and Mohandas, 2009), and severe anemia may trigger
KSHV lytic replication by inducing hypoxia, a well characterized
condition involved in the reactivation of KSHV from latency
and the promotion of KS tumorigenesis (Stolka et al., 2014).
As mentioned earlier, a healthy host immune system suppresses
KSHV lytic replication, however, impairment of B-cell and
T-cell immunity resulting from repeated infections of malarial
parasite can lead to viral reactivation and thus could potentially
enhance the infectivity and/or transmission of KSHV (Nalwoga
et al., 2015). In addition to the immune suppressive eﬀects of
malarial parasite infection, Quinine and its derivatives, the drugs
that are extensively used to treat malaria, may exert immune
suppressive eﬀects on the malaria patient and consequently
trigger KSHV lytic replication (Ruocco et al., 2011). Furthermore,
person-to-person transmission of KSHV could be facilitated
by the bites of female Anopheles mosquitoes along with the
transmission of malarial parasites. While experimental evidences
demonstrating direct molecular mechanisms of interactions
between KSHV and malarial parasite are lacking; Conant et al.
(2013) have proposed an interesting potential molecular link
between malarial infection and KSHV reactivation. In malaria,
the parasite-infected red blood cells (IRBCs) are sequestered
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from the peripheral circulation by adherence to microvascular
endothelium of various organs. This process is critical for
the virulence of P. falciparum. The sequestration is mediated
by direct interactions between the members of P. falciparum
erythrocyte membrane protein 1 (pfEMP-1), family of parasite
encoded proteins that are expressed on the surface of IRBCs
and their cognate host receptors expressed on the surface of
endothelial cells. CD36 is the main host endothelial cell receptor
that mediates the adherence of IRBCs (Gowda et al., 2013).
Conant et al. (2013) found that cross-linking of CD36 with
a recombinant peptide derived from CD36 binding domain
of pfEMP-1 antigen could revoke KSHV latency, presumably
through activation of some of the signal transduction pathways
that lead to an activation of KSHV-RTA promoter.
Co-infection with other parasites such as helminth and
Mansonella perstans may inﬂuence KSHV pathogenesis by
modulating innate and adaptive antiviral host immune response
that may result into an enhanced lytic reactivation and/or
KSHV infectivity (Damania and Dittmer, 2014). While speciﬁc
contribution of parasite co-infections on KSHV pathogenesis
has not been extensively studied, one cross-sectional study has
demonstrated a positive correlation betweenKSHV seropositivity
and parasite co-infection with hookworms or M. perstans
(Wakeham et al., 2011).
Summing up, malarial and other parasite infections are a likely
risk factor for KSHV infection and/or reactivation, but further
epidemiological and in-lab studies are needed to underpin the
role of parasite co-infections in initiation and progression of
KSHV pathogenesis.
SUMMARY
Kaposi’s sarcoma-associated herpesvirus induced pathologies
are multi-factorial diseases emerging from extremely complex
interactions involving KSHV, countless host factors, and
polymicrobial co-infections. While enormously complex
interplay of multiple microbial interactions and how co-infected
host responds to these interactions with regards to KSHV
associated cancers is not well understood, it is clear that co-
pathogenic infections have a potential to aﬀect KSHV infection
and pathogenesis (Figure 1). Additional epidemiological and
experimental studies regarding interactions between KSHV
and its frequently co-infecting microbes can impart better
knowledge of underlying microbial synergy and help in deﬁning
new strategies for superior management of KSHV induced
pathologies. It is becoming increasingly important to detect
co-infecting pathogens and consider synergistic polymicrobial
interactions while treating patients for a particular disease, as
co-infecting pathogens can impact the overall outcome of the
associated pathogenesis through a variety of mechanisms.
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